Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival

Objective: To examine the proportion of migrants from Sub-Saharan Africa entering the Swiss HIV Cohort Study (SHCS) and to compare these participants with participants from Northwestern Europe for access to antiretroviral therapy, progression to AIDS and survival. Design: Prospective national cohort study of HIV-1-infected adults from seven HIV centres in Switzerland. Methods: Trends in the proportion of participants from Sub-Saharan Africa were followed in 11 872 HIV-infected adults entering the SHCS from 1984 to 2001. Survival methods were used to compare uptake of antiretroviral therapy, survival and progression to AIDS in the 2684 participants from Sub-Saharan Africa and Northwest Europe enrolled from 1997–2001. Results: There was a steady increase in the proportion of Sub-Saharan African participants over time, reaching 11.9% in 1997–2001. These participants were more likely to be younger, female, to have been infected by heterosexual intercourse and had lower CD4 cell counts at presentation. There were no differences between Sub-Saharan Africans and Northwest Europeans in uptake of triple antiretroviral therapy, progression to AIDS or survival up to 48 months after starting treatment. Tuberculosis was the most frequent AIDS-defining event in Sub-Saharan African patients. Conclusions: There is no evidence that access to potent antiretroviral therapy is influenced by geographic origin of participants. The prognosis of Sub-Saharan African patients on triple therapy is equivalent to that of Northwest European patients. Future research should address wider issues about access to specialist health services for HIV-infected people from Sub-Saharan Africa.

[1]  Evan Wood,et al.  Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996 , 2002, AIDS.

[2]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[3]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[4]  R. Wood,et al.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study , 2002, The Lancet.

[5]  K. Ariyoshi,et al.  Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy , 2002, AIDS.

[6]  A. Cozzi-Lepri,et al.  The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000 , 2002, HIV medicine.

[7]  C. Mahé,et al.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? , 2002, AIDS.

[8]  R. Salamon,et al.  Clinical and Biological Evolution of HIV‐1 Seroconverters in Abidjan, Côte d’Ivoire, 1997‐2000 , 2002, Journal of acquired immune deficiency syndromes.

[9]  C. Mahé,et al.  Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. , 2002, BMJ : British Medical Journal.

[10]  A. Copas,et al.  Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. , 2001, AIDS.

[11]  L. Calza,et al.  HIV disease among immigrants coming to Italy from outside of the European Union: a case-control study of epidemiological and clinical features , 2001, Epidemiology and Infection.

[12]  Neff Walker,et al.  The global impact of HIV/AIDS , 2001, Nature.

[13]  G. Smith,et al.  Learning to live with complexity: ethnicity, socioeconomic position, and health in Britain and the United States. , 2000, American journal of public health.

[14]  P. Francioli,et al.  Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. , 2000, Schweizerische medizinische Wochenschrift.

[15]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[16]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[17]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[18]  A. Telenti,et al.  Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. , 1999, Journal of acquired immune deficiency syndromes.

[19]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[20]  M. Egger,et al.  Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland , 1998, AIDS.

[21]  J. Stephenson,et al.  Disease progression and survival in HIV‐1‐infected Africans in London , 1998, AIDS.

[22]  R. Bhopal,et al.  Spectre of racism in health and health care: lessons from history and the United States , 1998, BMJ.

[23]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[24]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[25]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[26]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[27]  The Swiss Hiv Cohort Study,et al.  The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics , 2005, Sozial- und Präventivmedizin.